3rd August 2021
Professor Jack Cuzick, Director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London and Theme Lead for Cancer Prevention & Risk Reduction at the Cancer Research UK Barts Centre, has been awarded a Queen Mary Impact Award for his research on human papilloma virus (HPV) screening for cervical cancer, which has transformed cervical cancer prevention programmes worldwide.
Read more19th July 2021
We spoke with Group Leader Dr Jun Wang and Postdoctoral Researcher Dr Anthony Anene from Barts Cancer Institute’s Centre for Cancer Genomics & Computational Biology about their most recent publication. Published in Patterns, the paper describes the development of a machine-learning tool called ACSNI that can be used to predict tissue-specific pathway components from large biological datasets.
Read more12th July 2021
Dr Susana Godinho, Group Leader in the Centre for Cancer Cell & Molecular Biology at Barts Cancer Institute, Queen Mary University of London, has recently received a Cancer Research UK Discovery Programme Foundation Award. The award of approximately £1.4 million over 6 years will support a research project that will investigate the impact of centrosome amplification in cancer.
Read more9th July 2021
A new study from Barts Cancer Institute, Queen Mary University of London, has demonstrated that immune cells can be stimulated to assemble into special structures within pancreatic cancer such that, at least in a pre-clinical model, researchers can demonstrate an improvement in the efficacy of chemotherapy.
Read more8th July 2021
A partnership between Queen Mary University of London and the University of Southampton has successfully bid for 45 studentships from the Medical Research Council (MRC), part of UK Research and Innovation (UKRI).
Read more29th June 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that could be used to aid in the diagnosis of pancreatic cancer. Findings from the new study suggest that a protein called pentraxin 3 may be a specific diagnostic biomarker – or biological measure – for pancreatic cancer, with the ability to differentiate pancreatic cancer from other non-cancerous conditions of the pancreas.
Read more